Liraglutide Pen Injection
Composition:
Each pre-filled pen contains Liraglutide 6mg/mL or 18mg/3mL, depending on the specific formulation, as the active ingredient.
Indications:
Liraglutide Pen Injection is primarily used for the management of Type 2 diabetes mellitus to improve blood sugar control in adults. It may also be prescribed for weight management in adults with obesity or overweight patients who have at least one weight-related comorbidity, such as hypertension, dyslipidemia, or type 2 diabetes. Liraglutide is also used in the treatment of cardiovascular risk reduction in individuals with established heart disease and Type 2 diabetes.
Mechanism of Action:
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the action of the natural hormone GLP-1, which stimulates insulin secretion in response to meals, reduces glucagon release (which prevents the liver from producing excess glucose), and slows gastric emptying, thereby promoting satiety (feeling of fullness). These actions help to lower blood glucose levels and promote weight loss by reducing appetite. Liraglutide also improves pancreatic beta-cell function, contributing to better blood sugar control.
Dosage:
The recommended starting dose of Liraglutide for Type 2 diabetes mellitus is 0.6mg once daily, administered subcutaneously (under the skin). This dose can be gradually increased to 1.2mg once daily, and, if necessary, further increased to a maximum of 1.8mg once daily based on individual patient needs and tolerance. For weight management, the recommended dose is 3mg once daily after a gradual dose escalation. It is important to follow the prescribed dosing regimen and adjust doses as directed by the healthcare provider.
Packaging:
Liraglutide is available in pre-filled pens, typically containing either 3mL or 18mg of Liraglutide, depending on the formulation. The pen is designed for subcutaneous injection, and each pen can deliver multiple doses, depending on the dosage prescribed
